Posted by Michael Wonder on 28 Jun 2026
Replimune announces FDA acceptance of RP1 biologics license application resubmission for advanced melanoma
26 June 2026 - FDA decision expected by 2 August 2026.
Replimune announced today that the US FDA has accepted for review the resubmission of the biologics license application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.
